Soluble appsα-based gene therapy in alzheimer’s disease

The present invention relates to a method of treating Alzheimer’s disease by administration to the subject of a therapeutically effective amount of a vector which comprises a nucleic acid molecule encoding for a polypeptide which is a soluble member of the APP (amyloid precursor protein) family.

More information (PDF)

Keywords: soluble amyloid precursor protein (APPsα)

Patent Application number: EP15305904.3

Inventors:

Jérôme BRAUDEAUNathalie CARTIER-LACAVEUlrike MUELLERAbel TOBIASChristian BUCHHOLZRomain FOL

Publications:

Acta Neuropathol. 2016 Feb;131(2):247-266. doi: 10.1007/s00401-015-1498-9. Epub 2015 Nov 4.

Reference:

BIO15161-T1